Predict your next investment

Private Equity
crossatlanticpartners.com

See what CB Insights has to offer

Investments

19

Portfolio Exits

6

Funds

6

Service Providers

1

About Cross Atlantic Partners

Cross Atlantic Partners (CAP) actively manages private equity funds for investment in developing healthcare and life sciences companies in the United States. We focus on later-stage private and public companies developing innovative drug discovery tools, devices, and services for human healthcare.

Cross Atlantic Partners Headquarter Location

551 Madison Ave 7th Floor

New York, New York, 10022,

United States

646-521-7500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Cross Atlantic Partners News

Labcyte Closes $5.3m Financing

Jan 9, 2013

By Angela Sormani Labcyte, a privately-held company advancing acoustic liquid handling, has closed a Series D financing led by the healthymagination fund, a part of GE Ventures. The $5.3 million round also included current Labcyte investors – Abingworth, Alloy Ventures, Cross Atlantic Partners, Delphi Ventures, H&Q Healthcare Investors and H&Q Life Sciences Investors. PRESS RELEASE Labcyte Inc., a privately-held company advancing acoustic liquid handling, today announced it has closed a Series D financing led by the healthymagination fund, a part of GE Ventures. The $5.3 million round also included current Labcyte investors: Abingworth, Alloy Ventures, Cross Atlantic Partners, Delphi Ventures, H&Q Healthcare Investors HQH +1.42% and H&Q Life Sciences Investors HQL +0.32% . Labcyte will use the investment to continue to expand its revolutionary liquid handling systems based on the use of acoustic energy to precisely and accurately transfer liquids. Combined with its automation platforms and novel software capabilities, Labcyte’s award-winning products offer unsurpassed control over the steps that are the backbone of life science research, molecular medicine, drug discovery and diagnostic programs. Since acoustic dispensing transfers liquids without contact and eliminates the use of pipettes and their associated problems, data quality and reliability are significantly improved while costs are substantially reduced. The Labcyte system allows for the ability to transfer very low volumes of liquids, resulting in further cost savings by minimizing the use of reagents, while conserving precious samples. It also provides the capability to miniaturize assays and thereby increase productivity and through-put, enabling significant advances in a wide range of life science applications. “Labcyte’s acoustic liquid handling products are well-established globally, with customers including pharmaceutical, biotechnology, diagnostic and contract research companies along with academic institutions. Our systems are being employed to further personalized medicine with multiple applications in genomics, proteomics, diagnostics and cell health,” said Mark Fischer-Colbrie, CEO and president of Labcyte. “Closing the funding will further enable us to add to our product lines and accelerate our growth.” The investment in Labcyte reflects GE’s continuing interest in life science tools, medical diagnostics solutions and the growing area of personalized medicine. The healthymagination fund is the healthcare investing group of GE Ventures and part of GE’s $6 billion healthymagination initiative, a global commitment to deliver better health to more people. “We are very pleased to add GE to our investor group,” said Fischer-Colbrie. “It’s a reflection of the high level of interest in the current broad-based and future uses of acoustic dispensing and the continued rapid adoption of products that can have a dramatic impact in life science.” Rafael Torres, healthymagination fund leader, GE Ventures said, “Innovations and research platforms, like Labcyte, are vital to improving healthcare quality and affordability. We are excited to invest and support Labcyte, a company positioned to serve a rapidly growing market, as it expands the breadth of its product portfolio.” About Labcyte Labcyte, a global biotechnology tools company headquartered in Sunnyvale, California, is revolutionizing liquid handling. Echo(R) liquid handling systems use sound to precisely transfer liquids without contact eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical industry, biotechnology firms, contract research organizations and academic institutions. Our customers work across a wide spectrum of scientific research including drug discovery, genomics, proteomics, diagnostics, personalized medicine and imaging mass spectrometry. Labcyte has 62 global patents, along with additional filings. About GE GE GE -1.09% works on things that matter. The best people and the best technologies taking on the toughest challenges. Finding solutions in energy, health and home, transportation and finance. Building, powering, moving and helping to cure the world. Not just imagining. Doing. GE works. SOURCE: Labcyte Inc.

Cross Atlantic Partners Investments

19 Investments

Cross Atlantic Partners has made 19 investments. Their latest investment was in Labcyte as part of their Series D - II on September 9, 2013.

CBI Logo

Cross Atlantic Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/20/2013

Series D - II

Labcyte

$0.48M

No

1

1/7/2013

Series D

Labcyte

$5.3M

No

6

11/8/2011

Series B - III

Vitals

$12M

No

10/21/2011

Series B - II

Subscribe to see more

$99M

Subscribe to see more

0

2/3/2011

Series B

Subscribe to see more

$99M

Subscribe to see more

0

Date

9/20/2013

1/7/2013

11/8/2011

10/21/2011

2/3/2011

Round

Series D - II

Series D

Series B - III

Series B - II

Series B

Company

Labcyte

Labcyte

Vitals

Subscribe to see more

Subscribe to see more

Amount

$0.48M

$5.3M

$12M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

6

0

0

Cross Atlantic Partners Portfolio Exits

6 Portfolio Exits

Cross Atlantic Partners has 6 portfolio exits. Their latest portfolio exit was Sapphire Digital on September 14, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/14/2021

Acquired

1

10/1/2019

Acquired

Subscribe to see more

Subscribe to see more

10

1/30/2019

Acquired

Subscribe to see more

Subscribe to see more

10

3/1/2016

Acq - Fin

Subscribe to see more

Subscribe to see more

10

10/27/2011

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/14/2021

10/1/2019

1/30/2019

3/1/2016

10/27/2011

Exit

Acquired

Acquired

Acquired

Acq - Fin

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Cross Atlantic Partners Fund History

6 Fund Histories

Cross Atlantic Partners has 6 funds, including Cross Atlantic Partners KS V LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/1/2004

Cross Atlantic Partners KS V LP

Early-Stage Venture Capital

Closed

$30M

1

7/1/2001

Cross Atlantic Partners IV LP

Subscribe to see more

Subscribe to see more

$99M

10

7/1/1997

Cross Atlantic Partners III

Subscribe to see more

Subscribe to see more

$99M

10

1/1/1996

Cross Atlantic Partners II

Subscribe to see more

Subscribe to see more

$99M

10

7/1/1994

Cross Atlantic Partners

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/1/2004

7/1/2001

7/1/1997

1/1/1996

7/1/1994

Fund

Cross Atlantic Partners KS V LP

Cross Atlantic Partners IV LP

Cross Atlantic Partners III

Cross Atlantic Partners II

Cross Atlantic Partners

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$30M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Cross Atlantic Partners Service Providers

1 Service Provider

Cross Atlantic Partners has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

Cross Atlantic Partners Team

1 Team Member

Cross Atlantic Partners has 1 team member, including current Managing Partner, Owner, Sandra Panem.

Name

Work History

Title

Status

Sandra Panem

Managing Partner, Owner

Current

Name

Sandra Panem

Work History

Title

Managing Partner, Owner

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.